Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Green Cross gets complete response letter from FDA for IVIG-SN
The requests raised by the FDA pertain only to Chemistry, Manufacturing and Controls (CMC). As the CRL did not cite efficacy or safety issues, Green Cross believes that
The requests raised by the FDA pertain only to Chemistry, Manufacturing and Controls (CMC). As the CRL did not cite efficacy or safety issues, Green Cross believes that
Under the partnership, WuXi Biologics will be the exclusive clinical manufacturer for IMP321 for Prima worldwide, excluding any manufacturing for the supply of China, Macau, Taiwan and Hong
The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to
The collaboration follows the recent acquisition of the technology for the manufacture of IFNα by Neovacs from AMEGABIOTECH. This license agreement will allow Neovacs to directly transfer AMEGABIOTECH's
The equity consideration for the 85.1% stake is $24m. Sun Pharma would also assume a debt of approximately $36m as part of this transaction. Biosintez is a Russian
The trial demonstrated that patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo. The company said it
The NDA submission was made in close proximity to World Diabetes Day, and during National Diabetes month in America – two annual events that remind us that type
The company’s latest report states that the impressive strength of the market over the next decade can be attributed to the increasing incorporation of premium-priced immune checkpoint inhibitors
Allergan acquired Chase for an upfront payment of $125 million (subject to certain adjustments) and additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201,
This project, to be named BL-1230, is the third project in-licensed under the framework of the Company’s strategic collaboration with Novartis Pharma AG for the screening and development